# Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

> **NCT06026514** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 27 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** B/HPIV3/S-6P

## Key facts

- **NCT ID:** NCT06026514
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-18
- **Primary completion:** 2025-01-16
- **Final completion:** 2025-06-30
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06026514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06026514, "Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06026514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*